Camizestrant with a CDK 4/6 inhibitor had a statistically significant and clinically meaningful improvement in PFS in ...

Medically reviewed by Isabel Casimiro, MD, PhD Hypogonadism is when the sex glands (gonads) produce little or no sex hormones ...

The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatme ...

Medically reviewed by Marla Anderson, MD HR+/HER2- breast cancer—or hormone receptor-positive, HER2-negative breast cancer—is ...

Interim data has shown benefits of the camizestrant combo over standard treatment in ESR1-mutant breast cancer.

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...

The early findings from the SERENA-6 trial indicate that the investigational oral SERD camizestrant provides a “highly ...